Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3007 An mRNA-based Classifier Identifies PanNETs with Different Clinicopathological Characteristics

Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms that varies from indolent to highly aggressive diseases. Previous studies have suggested alterations of ATRX/DAXX as biomarkers of dismal prognosis, yet inconclusive data (especially in the metastatic setting) prevent those biomarkers to be used as routine clinical tests.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Vicentini C, Barbi S, Bersani S, Rusev B, Lawlor R,

Keywords: PanNET, gene expression profile, ATRX/DAXX mutations, patients’ stratification.,

#1054 Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors

Introduction: Hepatic arterial embolization with 90Y-labelled microspheres is a method of delivering radioactivity to liver tumors, that has been used to treat primary hepatocellular carcinomas and liver metastases from colorectal carcinomas and neuroendocrine tumors.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Granberg D

Authors: Ebeling-Barbier C, Garske-Roman U, Antonodimitrakis P, Sandström M, Nyman R,

Keywords: radioembolization, neuroendocrine, liver metastases,

#752 First In Vitro Study of Human Gastroenteropancreatic Neuroendocrine Tumors: Comparative Effect of Octreotide, Pasireotide and Everolimus

Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Albertelli M, Mohamed A, Arvigo M, Grillo F, Barbieri F,

Keywords: neuroendocrine, primary cultures, drugs,

#587 First in vitro study of Human GastroEnteroPancreatic-Neuroendocrine Tumors: comparative effect of Octreotide, Pasireotide and Everolimus.

Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: Albertelli M, Mohamed A, Marica A, Grillo F, Barbieri F,

Keywords: neuroendocrine, primary cultures, drugs,